Table 1.
Baseline demographic, clinical, and medical therapy of the study patients
| Variables | Study patients (n = 341) |
|---|---|
| Age (years) | 50 (38–60) |
| Male gender [n (%)] | 172 (50.4) |
| Hypertension [n (%)] | 114 (33.4) |
| Diabetes mellitus [n (%)] | 48 (14.1) |
| Smoking [n (%)] | 94 (27.4) |
| NYHA class | |
| NYHA class 1 | 246 (72.4) |
| NYHA class 2 | 95 (27.6 |
| BMI (kg/m2) | 25.9 (23.4–28.1) |
| Symptoms (=yes) [n (%)] | 298 (87.4) |
| Palpitations | 198 (58.1) |
| Skipped/dropped beats | 33 (9.7) |
| Chest discomfort | 26 (7.6) |
| Dizziness | 16 (4.7) |
| Fatigue | 20 (5.9) |
| Syncope | 5 (1.5) |
| Current medical therapy | |
| β‐blocker [n (%)] | 160 (46.9) |
| Calcium channel blocker [n(%)] | 38 (11.1) |
| Amiodarone [n (%)] | 10 (2.9) |
| Propafenone [n (%)] | 11 (3.2) |
| History of medical therapy | |
| β‐blocker [n (%)] | 105 (30.8) |
| Amiodarone [n (%)] | 8 (2.3) |
| Propafenone [n (%)] | 10 (2.9) |
| History of PVC Ablation [n(%)] | 17 (5.0) |
| EF (%) | 60 (55–65) |
Data are expressed as median interquartile range and count (percentage).
Abbreviations: BMI, body mass index; EF, ejection fraction; LV, left ventricle; PVC, premature ventricular complex.